Coherent Capital

Braid Health Raises $9M in Seed + Series A Funding

Braid Health, a San Francisco, CA-based digital health innovation company that develops AI-powered diagnostic tools for radiology, closed $9m in seed and Series A funding rounds. The company intends to use the funds to continue to expand operations and its business reach, as well as increase its development efforts.

The company will use Seed and Series A investment to:

Build the healthcare industry’s most advanced, AI-driven diagnostic imaging platform,
Develop the Braid Network, a technology platform connecting a virtual network of healthcare specialists to improve care delivery and drive cost out of the system.

Founded by Kevin Quennesson and Alessandro Sabatelli, Braid Health provides urgent care centers, health systems and retail pharmacies with an AI-powered, end-to-end diagnostic collaboration platform for radiology and the healthcare industry.

The round was led by Lux Capital with participation from 01 Advisors, and Rucker Park Capital.

Wesley King - Biohacking Investment Banker

Maggie SaundersMay 14, 2020

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. Coherent Capital, LLC and Finalis Securities LLC are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck

CoherentCapital.com is a website operated by Coherent Capital, LLC, a privately held California limited liability company. Coherent Capital, LLC provides financial and strategic advisory, consulting services, mergers and acquisitions services, fairness opinions, etc.].

Coherent Capital, LLC is not a registered broker-dealer, and Finalis Securities LLC and Coherent Capital, LLC are separate, unaffiliated entities.

Finalis does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security. You can review the brokercheck for Finalis here. This website is intended solely for qualified investors. Investments in private offerings and startup investments in particular are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in such offerings. Companies seeking startup investments tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted stock that may be subject to holding period requirements. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest. Business Continuity Plan for Finalis.